97 related articles for article (PubMed ID: 33420626)
1. Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence.
El Hasbani G; Viola M; Sciascia S; Taher AT; Uthman I
Rheumatol Ther; 2021 Mar; 8(1):81-94. PubMed ID: 33420626
[TBL] [Abstract][Full Text] [Related]
2. Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss.
Cecchi I; Radin M; Rubini E; Foddai SG; Barinotti A; Roccatello D; Sciascia S
Lupus; 2021 May; 30(6):884-892. PubMed ID: 33593163
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management.
Sayar Z; Moll R; Isenberg D; Cohen H
Thromb Res; 2021 Feb; 198():213-221. PubMed ID: 33485122
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy and Management in Women with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Obstetric Antiphospholipid Syndrome.
Castro-Gutierrez A; Young K; Bermas BL
Med Clin North Am; 2021 Mar; 105(2):341-353. PubMed ID: 33589107
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?
Mormile I; Granata F; Punziano A; de Paulis A; Rossi FW
Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33535377
[TBL] [Abstract][Full Text] [Related]
6. Imaging in Diagnosis of Systemic Sclerosis.
Rutka K; Garkowski A; Karaszewska K; Łebkowska U
J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33445449
[TBL] [Abstract][Full Text] [Related]
7. Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers.
Calcaterra I; Ambrosino P; Vitelli N; Lupoli R; Orsini RC; Chiurazzi M; Maniscalco M; Di Minno MND
Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33513790
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases.
Cavalli G; Colafrancesco S; Emmi G; Imazio M; Lopalco G; Maggio MC; Sota J; Dinarello CA
Autoimmun Rev; 2021 Mar; 20(3):102763. PubMed ID: 33482337
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stromal cells for systemic sclerosis treatment.
Farge D; Loisel S; Lansiaux P; Tarte K
Autoimmun Rev; 2021 Mar; 20(3):102755. PubMed ID: 33476823
[TBL] [Abstract][Full Text] [Related]
10. A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response.
Rossi D; Sciascia S; Cecchi I; Saracco M; Montabone E; Modena V; Pellerito R; Carignola R; Roccatello D
J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33466837
[TBL] [Abstract][Full Text] [Related]
11. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation.
Devreese KMJ; de Groot PG; de Laat B; Erkan D; Favaloro EJ; Mackie I; Martinuzzo M; Ortel TL; Pengo V; Rand JH; Tripodi A; Wahl D; Cohen H
J Thromb Haemost; 2020 Nov; 18(11):2828-2839. PubMed ID: 33462974
[TBL] [Abstract][Full Text] [Related]
12. Occupational exposure to respirable crystalline silica and risk of autoimmune rheumatic diseases: a nationwide cohort study.
Boudigaard SH; Schlünssen V; Vestergaard JM; Søndergaard K; Torén K; Peters S; Kromhout H; Kolstad HA
Int J Epidemiol; 2021 Aug; 50(4):1213-1226. PubMed ID: 33462590
[TBL] [Abstract][Full Text] [Related]
13. Arg206Cys substitution in
Coke LN; Wen H; Comeau M; Ghanem MH; Shih A; Metz CN; Li W; Langefeld CD; Gregersen PK; Simpfendorfer KR
Ann Rheum Dis; 2021 Jun; 80(6):782-787. PubMed ID: 33455918
[TBL] [Abstract][Full Text] [Related]
14. Increased Risk of Valvular Heart Disease in Systemic Sclerosis: An Underrecognized Cardiac Complication.
Kurmann RD; El-Am EA; Radwan YA; Sandhu AS; Crowson CS; Matteson EL; Warrington KJ; Mankad R; Makol A
J Rheumatol; 2021 Jul; 48(7):1047-1052. PubMed ID: 33452164
[TBL] [Abstract][Full Text] [Related]
15. Oxidative Stress and Lipid Mediators Modulate Immune Cell Functions in Autoimmune Diseases.
Wójcik P; Gęgotek A; Žarković N; Skrzydlewska E
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33450863
[TBL] [Abstract][Full Text] [Related]
16. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
[TBL] [Abstract][Full Text] [Related]
17. Involvement of RAGE and Oxidative Stress in Inflammatory and Infectious Skin Diseases.
Guarneri F; Custurone P; Papaianni V; Gangemi S
Antioxidants (Basel); 2021 Jan; 10(1):. PubMed ID: 33435332
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis.
Feng X; Li XQ; Jiang Z
Clin Rheumatol; 2021 Aug; 40(8):3039-3051. PubMed ID: 33426631
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition.
Mendoza FA; Piera-Velazquez S; Jimenez SA
Transl Res; 2021 May; 231():139-158. PubMed ID: 33422651
[TBL] [Abstract][Full Text] [Related]
20. Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action.
Noordermeer T; Molhoek JE; Schutgens REG; Sebastian SAE; Drost-Verhoef S; van Wesel ACW; de Groot PG; Meijers JCM; Urbanus RT
J Thromb Haemost; 2021 Apr; 19(4):1018-1028. PubMed ID: 33421291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
